Health Care [ 5/12 ] | Pharmaceuticals [ 13/73 ]
NASDAQ | Common Stock
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer.
The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers.
It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University.
The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024.
Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 25 | -0.16 Increased by +96.71% | -8.75 Increased by +98.17% |
| May 13, 25 | 22.44 Increased by +11.91 K% | -0.27 Increased by +8.57 K% |
| Mar 31, 25 | 26.60 Increased by +14.10 K% | -0.25 Increased by +10.74 K% |
| Nov 12, 24 | -8.81 Decreased by -3.73 K% | -6.25 Decreased by -41.03% |
| Aug 15, 24 | -4.87 Decreased by -2.33 K% | -6.25 Increased by +22.16% |
| May 15, 24 | -0.19 Increased by +32.14% | -0.23 Increased by +17.39% |
| Mar 14, 24 | -0.19 Increased by +26.92% | -0.25 Increased by +24.00% |
| Nov 14, 23 | -0.23 Increased by +11.54% | -0.29 Increased by +20.69% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 2.73 M Increased by +4.69 K% | -915.00 K Increased by +99.26% | Decreased by -33.48% Increased by +99.98% |
| Mar 31, 25 | 57.00 K Increased by +1.79% | 15.08 M Increased by +402.69% | Increased by +26.46 K% Increased by +397.38% |
| Dec 31, 24 | 56.00 K Increased by 0.00% | 81.93 M Increased by +2.06 K% | Increased by +146.30 K% Increased by +2.06 K% |
| Sep 30, 24 | 57.00 K Increased by 0.00% | -8.47 M Decreased by -78.84% | Decreased by -14.87 K% Decreased by -78.84% |
| Jun 30, 24 | 57.00 K Increased by 0.00% | -123.14 M Decreased by -2.80 K% | Decreased by -216.04 K% Decreased by -2.80 K% |
| Mar 31, 24 | 56.00 K Increased by 0.00% | -4.98 M Increased by +13.71% | Decreased by -8.90 K% Increased by +13.71% |
| Dec 31, 23 | 56.00 K Increased by 0.00% | -4.18 M Increased by +22.80% | Decreased by -7.47 K% Increased by +22.80% |
| Sep 30, 23 | 57.00 K Increased by 0.00% | -4.74 M Increased by +12.21% | Decreased by -8.31 K% Increased by +12.21% |